Initiating Transdermal Estradiol Therapy in Turner's Syndrome

Stopped early · Phase 1

Conditions studied: Turner's Syndrome

In brief

This is a multicenter, randomized, controlled, semi-blinded study to compare two low doses of estradiol administered by recently available transdermal patches for the initiation of puberty in Turner syndrome girls 11.5-13.0 years old in conjunction with growth hormone (GH) therapy. The specific hypotheses to be tested are: when combined with growth hormone (GH) treatment, low dose transdermal estradiol (LTE2) replacement will be more effective in stimulating feminization, height velocity, and bone mineral density without compromising growth potential than very low dose transdermal estradiol (VLTE2), which will in turn be superior to GH alone in effects on feminization, height velocity, and bone mineral density.

Key facts

Study ID
NCT00870220
Run by
University of Chicago
People needed
1
Starts
2009-04-01
Expected to finish
2011-03-01
Last updated by the study team
2014-03-11

Who can join

Age: 12 and older, up to 13. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.